NCT06429306View on ClinicalTrials.gov

Study of Dexycu in Treating Intraocular Inflammation

PHASE3CompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

November 24, 2023

Study Completion Date

April 9, 2024

Conditions
InflammationCataract
Interventions
DRUG

Dexycu

5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone

DRUG

Placebo

Acetyl triethyl citrate

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Ocumension Therapeutics (Shanghai) Co., Ltd

INDUSTRY